Neuried, Germany, 10 June 2025 – AMSilk, a global leader in advanced biomaterials based on silk proteins, today announces its expansion into the consumer care market with the launch of AMSilk4Shine and AMSilk4Care. AMSilk4Shine is an innovative, silk protein-based ingredient designed to provide a more sustainable, high-performance alternative to traditional petroleum-based polymers which are for […]
CNS specialist continues growth strategy across Europe and beyond, optimizing commercial efficiency and maintaining strong focus on innovation Barcelona, Spain and Düsseldorf, Germany – 14 November 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, marked the sixth anniversary since its rebranding as Neuraxpharm […]
Biocomposites SRL will support sales of STIMULAN, NanoBone, genex and SYNICEM Spacers throughout Italy New team has been hired and first sales have already taken place Keele, UK, 16 January 2024 – Biocomposites, an international medical devices company that engineers, manufactures and markets world-leading products for use in infection management in bone and soft tissue, is pleased […]
Acquisition of Brain Therapeutics with operations in Greece, Cyprus and the Balkan countries Dusseldorf and Barcelona, March 8th, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today announces the expansion of its business in Southeast Europe through the acquisition of Brain Therapeutics, a CNS-focused marketing and distribution […]
Chord Therapeutics was launched by Omega Funds in October 2020 to develop new oral treatments for rare neuroinflammatory diseases Merck to accelerate development of Chord’s innovative pipeline for generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD) Focused expansion in neuroinflammatory diseases builds on Merck’s existing neurology portfolio in Multiple Sclerosis (MS) Geneva, December […]
